

# Bahriye Aktas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016526/publications.pdf>

Version: 2024-02-01

135  
papers

5,011  
citations

147801

31  
h-index

95266

68  
g-index

143  
all docs

143  
docs citations

143  
times ranked

5953  
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis. PLoS ONE, 2022, 17, e0262257.	2.5	2
2	Abstract P2-01-16: Targeted sequencing of plasma-derived vs. urinary cfDNA from patients with triple negative breast cancer. Cancer Research, 2022, 82, P2-01-16-P2-01-16.	0.9	0
3	Heterogeneity between Core Needle Biopsy and Synchronous Axillary Lymph Node Metastases in Early Breast Cancer Patientsâ€”A Comparison of HER2, Estrogen and Progesterone Receptor Expression Profiles during Primary Treatment Regime. Cancers, 2022, 14, 1863.	3.7	5
4	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2â€” Early Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2557-2567.	1.6	49
5	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical Cancer Research, 2022, 28, 4995-5003.	7.0	6
6	An Observational Study on Breast Cancer Survival and Lifestyle Related Risk Factors. In Vivo, 2021, 35, 1007-1015.	1.3	7
7	CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 15.	1.7	5
8	Early response by <scp>MR</scp> imaging and ultrasound as predictor of pathologic complete response to 12â€”week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the <scp>WSG ADAPT</scp> subtrials. International Journal of Cancer, 2021, 148, 2614-2627.	5.1	5
9	Gene Expressionâ€”Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research, 2021, 27, 2148-2158.	7.0	12
10	Cell and Nucleus Shape as an Indicator of Tissue Fluidity in Carcinoma. Physical Review X, 2021, 11, .	8.9	46
11	FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo. Cancers, 2021, 13, 956.	3.7	10
12	Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast Cancer Research, 2021, 23, 36.	5.0	7
13	The Mechanical Fingerprint of Circulating Tumor Cells (CTCs) in Breast Cancer Patients. Cancers, 2021, 13, 1119.	3.7	8
14	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18
15	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. Journal of Clinical Oncology, 2021, 39, 504-504.	1.6	3
16	Update Breast Cancer 2021 Part 2 â€” Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2021, 81, 539-548.	1.8	6
17	Update Breast Cancer 2021 Part 1 â€” Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2021, 81, 526-538.	1.8	10
18	The Importance of Clinical Examination under General Anesthesia: Improving Parametrial Assessment in Cervical Cancer Patients. Cancers, 2021, 13, 2961.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	3.7	11
20	The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. <i>Breast</i> , 2021, 59, 58-66.	2.2	4
21	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	2.8	14
22	Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390.	0.0	0
23	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	5.1	27
24	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	3.2	18
25	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	4.1	33
26	Quality of life and associated factors after surgical treatment of vulvar cancer by vulvar field resection (VFR). <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 191-201.	1.7	7
27	Postoperative non-traumatic compartment syndrome (PNCS) in gynecologic surgery. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1013-1019.	1.7	0
28	Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial. , 2020, , .		2
29	Abstract P4-06-06: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 149 breast cancer patients - indicating tumoral heterogeneity. , 2020, , .		0
30	Abstract 4604: Can breast cancer cells be distinguished from blood cells by mechanical parameters? A label-free CTC detection approach. , 2020, , .		0
31	Use of a microsurgical vascular clip system (Yasargil clip) in laparoscopic fibroid enucleation. <i>Journal of the Turkish German Gynecology Association</i> , 2020, 21, 305-307.	0.6	1
32	Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1316-1326.	10.7	39
33	Roadmap to Local Tumour Growth: Insights from Cervical Cancer. <i>Scientific Reports</i> , 2019, 9, 12768.	3.3	8
34	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69 – GeparSepto. <i>Journal of Clinical Oncology</i> , 2019, 37, 2226-2234.	1.6	95
35	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808.	1.6	85
36	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27

#	ARTICLE	IF	CITATIONS
37	Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. Journal of the National Cancer Institute, 2018, 110, 628-637.	6.3	88
38	Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 67-76.	6.4	49
39	Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 622-629.	6.4	41
40	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. Clinical Chemistry, 2018, 64, 1054-1062.	3.2	55
41	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 172, 93-104.	2.5	28
42	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer, 2018, 18, 541.	2.6	6
43	Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.. Journal of Clinical Oncology, 2018, 36, 12102-12102.	1.6	2
44	Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.. Journal of Clinical Oncology, 2018, 36, 573-573.	1.6	3
45	Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. Journal of Clinical Oncology, 2018, 36, 572-572.	1.6	14
46	Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. European Journal of Radiology, 2017, 89, 14-19.	2.6	28
47	Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer. Gynecologic Oncology Reports, 2017, 20, 4.	0.6	3
48	Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. Molecular Medicine Reports, 2017, 15, 2957-2968.	2.4	9
49	Technique of ICG-guided Targeted Compartmental Pelvic Lymphadenectomy (TCL) combined with Pelvic Peritoneal Mesometrial Resection (PMMR) for locoregional control of endometrial cancer – A proposal. Gynecologic Oncology Reports, 2017, 20, 125-126.	0.6	13
50	Efficacy and safety of nab-paclitaxel 125Âmg/m2 and nab-paclitaxel 150Âmg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBC 69). Breast Cancer Research and Treatment, 2017, 163, 495-506.	2.5	20
51	Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation. Gynecologic Oncology Reports, 2017, 20, 22-23.	0.6	4
52	Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. Clinical Chemistry, 2017, 63, 1585-1593.	3.2	45
53	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Research and Treatment, 2017, 165, 573-583.	2.5	149
54	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Scientific Reports, 2017, 7, 17307.	3.3	16

#	ARTICLE	IF	CITATIONS
55	Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part). <i>Journal of Gynecologic Oncology</i> , 2017, 28, e68.	2.2	11
56	Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. <i>PLoS ONE</i> , 2017, 12, e0172553.	2.5	34
57	Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>		
58	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017, 35, 3046-3054.	1.6	114
59	Abstract 3777: RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. , 2017, , .		2
60	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1061.	1.6	25
61	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 504-504.	1.6	10
62	Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 573-573.	1.6	3
63	Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 67-72.	0.8	4
64	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	1.1	14
65	Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12547-e12547.	1.6	0
66	Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1012-1012.	1.6	0
67	Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5611-TPS5611.	1.6	0
68	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. <i>Scientific Reports</i> , 2016, 6, 26355.	3.3	25
69	Current role of liquid biopsy in metastatic breast cancer and future perspectives. <i>Der Gynakologe</i> , 2016, 49, 680-684.	1.0	0
70	Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. <i>Breast Care</i> , 2016, 11, 323-327.	1.4	7
71	Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer. <i>Future Science OA</i> , 2016, 2, FSO145.	1.9	3
72	Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system. <i>Gynecologic Oncology Reports</i> , 2016, 16, 24.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. <i>Gynecologic Oncology Reports</i> , 2016, 18, 14.	0.6	4
74	Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 522.	2.6	71
75	Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine green (ICG). <i>Journal of Surgical Oncology</i> , 2016, 113, 554-559.	1.7	31
76	Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 153-160.	1.7	19
77	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto GBC 69): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 345-356.	10.7	316
78	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016, 34, 2341-2349.	1.6	246
79	Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer. <i>Cancer Research</i> , 2016, 76, 5010-5010.	0.9	1
80	Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 556-556.	1.6	4
81	The DETECT study concept: Individualized therapy of metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS634-TPS634.	1.6	6
82	Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	1.6	91
83	Abstract 502: Gene expression signatures in circulating tumor cells are prognostic for metastatic lesions in breast cancer patients and correlate with response to therapy. <i>Cancer Research</i> , 2016, 76, 502-502.	0.9	1
84	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. <i>Anticancer Research</i> , 2016, 36, 967-74.	1.1	10
85	Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 87-92.	2.5	9
86	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	1.6	108
87	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 141-149.	2.5	19
88	[18F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 56-65.	6.4	115
89	Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1814-1824.	6.4	85
90	Abstract 383: The AdnaCollector, a new fully automated selection for circulating tumor cells in blood of primary and metastatic breast cancer patients. <i>Cancer Research</i> , 2015, 75, 383-383.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial. , 2015, , .		4
92	Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. Cancer Research, 2015, 75, S2-07-S2-07.	0.9	11
93	Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 1032-1032.	1.6	9
94	Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.. Journal of Clinical Oncology, 2015, 33, 506-506.	1.6	15
95	Abstract P6-08-39: Influence of lifestyle factors and tumor cell dissemination in 632 early breast cancer patients. , 2015, , .		0
96	Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. , 2015, , .		2
97	Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial.. Journal of Clinical Oncology, 2015, 33, e11555-e11555.	1.6	0
98	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2015, 33, TPS11109-TPS11109.	1.6	0
99	Abstract 372: Expression profiling of circulating tumor cells: A prognostic and predictive biomarker in metastatic breast cancer. , 2015, , .		0
100	Correlation of Standardized Uptake Value and Apparent Diffusion Coefficient in Integrated Whole-Body PET/MRI of Primary and Recurrent Cervical Cancer. PLoS ONE, 2014, 9, e96751.	2.5	51
101	The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. Oncology Letters, 2014, 7, 2007-2012.	1.8	5
102	ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. Clinical Chemistry, 2014, 60, 1282-1289.	3.2	101
103	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. Journal of Clinical Oncology, 2014, 32, 524-524.	1.6	1
104	Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.. Journal of Clinical Oncology, 2014, 32, e22032-e22032.	1.6	1
105	Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.. Journal of Clinical Oncology, 2014, 32, e12007-e12007.	1.6	0
106	Abstract 3066: Establishment of a new method for the selection and detection of circulating tumor cells in metastatic breast cancer patients. , 2014, , .		0
107	Abstract 3076: A fully automated q-PCR-based circulating tumor cell analysis using the AlereTMq-Analyzer test platform. , 2014, , .		2
108	Circulating tumor cells in breast cancer. Clinica Chimica Acta, 2013, 423, 39-45.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	2.5	28
110	Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as "total mesometrial resection (TMMR)" by M HÄ¶ckel translated to robotic surgery (rTMMR). <i>World Journal of Surgical Oncology</i> , 2013, 11, 211.	1.9	25
111	Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M HÄ¶ckel translated to robotic surgery. <i>World Journal of Surgical Oncology</i> , 2013, 11, 198.	1.9	25
112	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 81-88.	2.5	3
113	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 503-510.	2.5	118
114	Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1049-1054.	1.0	18
115	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	1.6	60
116	Definition of Compartment Based Radical Surgery in Uterine Cancer"Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael HÄ¶ckel Translated to Robotic Surgery. <i>ISRN Obstetrics &amp; Gynecology</i> , 2013, 2013, 1-17.	1.2	20
117	Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. <i>Oncology Reports</i> , 2013, 30, 441-447.	2.6	11
118	A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1141-TPS1141.	1.6	0
119	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5575-5575.	1.6	0
120	Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrow.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11516-e11516.	1.6	0
121	Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. <i>Anticancer Research</i> , 2013, 33, 329-36.	1.1	23
122	Prognostic impact of circulating tumor cells assessed with the CellSearch System®, and AdnaTest Breast®, in metastatic breast cancer patients: the DETECT study. <i>Breast Cancer Research</i> , 2012, 14, R118.	5.0	160
123	Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1077-1077.	1.6	1
124	Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 552-552.	1.6	1
125	DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1146-TPS1146.	1.6	1
126	Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10599-10599.	1.6	1



#	ARTICLE	IF	CITATIONS
127	Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R71.	5.0	44
128	Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 822-830.	2.5	97
129	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. <i>Gynecologic Oncology</i> , 2011, 122, 356-360.	1.4	127
130	Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. <i>Anticancer Research</i> , 2011, 31, 3623-8.	1.1	25
131	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 403-412.	2.5	330
132	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 581-590.	2.5	198
133	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R46.	5.0	658
134	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. <i>Breast Cancer Research</i> , 2009, 11, R59.	5.0	217
135	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	1.8	36